Dutch court orders Merck to stop making Keytruda in Europe
A Dutch court ruled that Merck infringed a patent on its subcutaneous Keytruda formulation and ordered the company to halt production and sales in several European nations.
Court ruling blocks new drug form
The legal decision specifically targets the subcutaneous version of the cancer treatment known as Keytruda. Merck must now stop manufacturing and marketing this medication across countries including France, Italy, Sweden, Switzerland, and the Netherlands. This order stems from a broader patent infringement dispute between Merck and Halozyme Therapeutics.
Older treatment remains available to patients
Patients requiring the drug will continue to have access to the existing intravenous version of Keytruda. That older formulation is not affected by the current patent dispute or the court order. The ruling does not impact the availability of this established method of administration.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.